Commerzbank Aktiengesellschaft FI Acquires 46,236 Shares of Amgen Inc. $AMGN

Commerzbank Aktiengesellschaft FI grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 31.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 194,785 shares of the medical research company’s stock after acquiring an additional 46,236 shares during the period. Amgen comprises about 1.4% of Commerzbank Aktiengesellschaft FI’s investment portfolio, making the stock its 23rd biggest position. Commerzbank Aktiengesellschaft FI’s holdings in Amgen were worth $68,535,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. increased its holdings in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares during the period. Curtis Advisory Group LLC purchased a new stake in shares of Amgen in the 4th quarter valued at $1,669,000. Adell Harriman & Carpenter Inc. boosted its holdings in shares of Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Amgen in the fourth quarter worth $22,441,000. Finally, Robinhood Asset Management LLC purchased a new position in shares of Amgen during the fourth quarter worth $17,526,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AMGN shares. Morgan Stanley lowered their price target on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. Weiss Ratings lowered Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Guggenheim upped their target price on Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Daiwa Securities Group dropped their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $356.62.

Amgen Trading Down 0.6%

AMGN stock opened at $364.17 on Tuesday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $196.55 billion, a P/E ratio of 25.34, a PEG ratio of 3.71 and a beta of 0.41. The company’s 50-day simple moving average is $348.38 and its 200-day simple moving average is $350.78.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.